Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.

MLA

Uy, Jonathan, et al. “Treatment of Advanced HIV Disease in Antiretroviral-Naïve HIV-1-Infected Patients Receiving Once-Daily Atazanavir/Ritonavir or Twice-Daily Lopinavir/Ritonavir, Each in Combination with Tenofovir Disoproxil Fumarate and Emtricitabine.” AIDS Care, vol. 23, no. 11, Nov. 2011, pp. 1500–04. EBSCOhost, https://doi.org/10.1080/09540121.2011.565033.

APA

Uy, J., Yang, R., Wirtz, V., Sheppard, L., Farajallah, A., & McGrath, D. (2011). Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine. AIDS Care, 23(11), 1500–1504. https://doi.org/10.1080/09540121.2011.565033

Chicago

Uy, Jonathan, Rong Yang, Victoria Wirtz, Louise Sheppard, Awny Farajallah, and Donnie McGrath. 2011. “Treatment of Advanced HIV Disease in Antiretroviral-Naïve HIV-1-Infected Patients Receiving Once-Daily Atazanavir/Ritonavir or Twice-Daily Lopinavir/Ritonavir, Each in Combination with Tenofovir Disoproxil Fumarate and Emtricitabine.” AIDS Care 23 (11): 1500–1504. doi:10.1080/09540121.2011.565033.